BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 37216165)

  • 1. Association between Ki67 expression and therapeutic outcome in colon cancer.
    Liu Q; Ran D; Wang L; Feng J; Deng W; Mei D; Peng Y; Du C
    Oncol Lett; 2023 Jun; 25(6):272. PubMed ID: 37216165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Topoisomerase II alpha expression and the benefit of adjuvant chemotherapy for postoperative patients with non-small cell lung cancer.
    Yan S; Shun-Chang J; Li C; Jie L; Ya-Li L; Ling-Xiong W
    BMC Cancer; 2010 Nov; 10():621. PubMed ID: 21067592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic value of Ki67 expression in HR-negative breast cancer before and after neoadjuvant chemotherapy.
    Tan QX; Qin QH; Yang WP; Mo QG; Wei CY
    Int J Clin Exp Pathol; 2014; 7(10):6862-70. PubMed ID: 25400769
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Evaluation value of preoperative peripheral blood lymphocyte-to-monocyte ratio on the prognosis of patients with stage III colon cancer].
    Chen J; Peng J; Fan W; Zhang R; Wang F; Zhou W; Xu D; Pan Z; Lu Z
    Zhonghua Wei Chang Wai Ke Za Zhi; 2019 Jan; 22(1):73-78. PubMed ID: 30703797
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic value of preoperative prognostic nutritional index and its associations with systemic inflammatory response markers in patients with stage III colon cancer.
    Peng J; Zhang R; Zhao Y; Wu X; Chen G; Wan D; Lu Z; Pan Z
    Chin J Cancer; 2017 Dec; 36(1):96. PubMed ID: 29268783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of Ki67 for adjuvant chemotherapy in node-negative, hormone receptor-positive breast cancer.
    Sutepvarnon A; Warnnissorn M; Srimuninnimit V
    J Med Assoc Thai; 2013 Feb; 96 Suppl 2():S60-6. PubMed ID: 23590023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic and predictive roles of DNA mismatch repair status in colon cancer patients treated with oxaliplatin-based chemotherapy: a retrospective study.
    Qin Q; Zhou AP; Yang L; Xu C; Sun YK; Zhang W; Wang JW; Zhong DS
    J Physiol Pharmacol; 2020 Aug; 71(4):. PubMed ID: 33316771
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated preoperative carcinoembryonic antigen (CEA) and Ki67 is predictor of decreased survival in IIA stage colon cancer.
    Peng Y; Wang L; Gu J
    World J Surg; 2013 Jan; 37(1):208-13. PubMed ID: 23052808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cutoff of 25% for Ki67 expression is a good classification tool for prognosis in colorectal cancer in the AJCC‑8 stratification.
    Tong G; Zhang G; Liu J; Zheng Z; Chen Y; Niu P; Xu X
    Oncol Rep; 2020 Apr; 43(4):1187-1198. PubMed ID: 32323802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Defective mismatch repair status as a prognostic biomarker of disease-free survival in stage III colon cancer patients treated with adjuvant FOLFOX chemotherapy.
    Zaanan A; Fléjou JF; Emile JF; Des GG; Cuilliere-Dartigues P; Malka D; Lecaille C; Validire P; Louvet C; Rougier P; de Gramont A; Bonnetain F; Praz F; Taïeb J
    Clin Cancer Res; 2011 Dec; 17(23):7470-8. PubMed ID: 21998335
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-associated Macrophages as Prognostic and Predictive Biomarkers for Postoperative Adjuvant Chemotherapy in Patients with Stage II Colon Cancer.
    Feng Q; Chang W; Mao Y; He G; Zheng P; Tang W; Wei Y; Ren L; Zhu D; Ji M; Tu Y; Qin X; Xu J
    Clin Cancer Res; 2019 Jul; 25(13):3896-3907. PubMed ID: 30988081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant chemotherapy with tegafur/uracil for more than 1 year improves disease-free survival for low-risk Stage II colon cancer.
    Hu JM; Chou YC; Wu CC; Hsiao CW; Lee CC; Chen CT; Hu SI; Liu WT; Jao SW
    J Chin Med Assoc; 2016 Sep; 79(9):477-88. PubMed ID: 27329402
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy.
    Kim JE; Hong YS; Kim HJ; Kim KP; Lee JL; Park SJ; Lim SB; Park IJ; Kim CW; Yoon YS; Yu CS; Kim JC; Hoon KJ; Kim TW
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3():S630-7. PubMed ID: 26271397
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic significance of Ki67 before and after neoadjuvant chemotherapy in breast cancer.
    Jones RL; Salter J; A'Hern R; Nerurkar A; Parton M; Reis-Filho JS; Smith IE; Dowsett M
    Breast Cancer Res Treat; 2009 Jul; 116(1):53-68. PubMed ID: 18592370
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic value of elastic lamina staining in patients with stage III colon cancer.
    Bi F; Li X; Zhang Y; Wang Z; Dong Q; Zhang J; Sun D
    World J Surg Oncol; 2022 Dec; 20(1):391. PubMed ID: 36503509
    [TBL] [Abstract][Full Text] [Related]  

  • 16. LINE-1 Methylation Status Correlates Significantly to Post-Therapeutic Recurrence in Stage III Colon Cancer Patients Receiving FOLFOX-4 Adjuvant Chemotherapy.
    Lou YT; Chen CW; Fan YC; Chang WC; Lu CY; Wu IC; Hsu WH; Huang CW; Wang JY
    PLoS One; 2014; 10(4):e0123973. PubMed ID: 25919688
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ERCC1, PARP-1, and AQP1 as predictive biomarkers in colon cancer patients receiving adjuvant chemotherapy.
    Abdelrahman AE; Ibrahim DA; El-Azony A; Alnagar AA; Ibrahim A
    Cancer Biomark; 2020; 27(2):251-264. PubMed ID: 31903985
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy.
    Kim ST; Lee J; Park SH; Park JO; Lim HY; Kang WK; Kim JY; Kim YH; Chang DK; Rhee PL; Kim DS; Yun H; Cho YB; Kim HC; Yun SH; Lee WY; Chun HK; Park YS
    Cancer Chemother Pharmacol; 2010 Sep; 66(4):659-67. PubMed ID: 20033812
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The prognostic effect of adjuvant chemotherapy in the colon cancer patients with solitary lymph node metastasis.
    Yeom SS; Lee SY; Kim CH; Kim HR; Kim YJ
    Int J Colorectal Dis; 2019 Aug; 34(8):1483-1490. PubMed ID: 31292725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Marked lymphovascular invasion, progesterone receptor negativity, and high Ki67 labeling index predict poor outcome in breast cancer patients treated with endocrine therapy alone.
    Kurebayashi J; Kanomata N; Shimo T; Yamashita T; Aogi K; Nishimura R; Shimizu C; Tsuda H; Moriya T; Sonoo H
    Breast Cancer; 2014 Mar; 21(2):214-22. PubMed ID: 22689016
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.